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Abstract: The recent massive reduction in the numbers of fresh Human African Trypanosomiasis
(HAT) infection has presented an opportunity for the global elimination of this disease. To prevent a
possible resurgence, as was the case after the reduced transmission of the 1960s, surveillance needs to
be sustained and the necessary tools for detection and treatment of cases need to be made available at
the points of care. In this review, we examine the available resources and make recommendations
for improvement to ensure the sustenance of the already achieved gains to keep the trend moving
towards elimination.
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1. Introduction
Trypanosoma brucei gambiense (T. b. gambiense) and Trypanosoma brucei rhodesiense (T. b. rhodesiense)
are the causative agents for the Human African trypanosomiasis (HAT), and together with Trypanosoma
brucei brucei (T. b. brucei) are the sub-species of Trypanosoma brucei. T. b. brucei, Trypanosoma congolense
(T. congolense) and Trypanosoma vivax (T. vivax) cause nagana in cattle. Trypanosoma evansi (T. evansi)
is responsible surra in camels and also cause disease in a wide range of domestic and wild animals
such as camelids, equines, cattle, buffaloes, sheep, goats, pigs, dogs, deer, gazelles, elephants, etc [1],
Trypanosoma equiperdum (T. equiperdum) is responsible for dourine of horses [2], while Trypanosoma
simae (T. simae) and Trypanosoma suis (T. suis) are the causal organisms for trypanosomiasis in pigs.
African trypanosomiasis occurring in animals, livestock and wild animals, is known as Animal African
Trypanosomiasis (AAT).
Sleeping sickness propagated by T. b. rhodesiense progresses swiftly while the T. b. gambiense
sleeping sickness develops more slowly. Symptoms usually includes fever, headache, muscle and
joint aches, enlarged lymph nodes, etc., (https://www.cdc.gov/parasites/sleepingsickness/disease.html).
Parasite invasion of the central nervous system occurs in a few weeks (for T. b. rhodesiense infection) or
in a few years (for T. b. gambiense infection), leading ultimately to coma and death if untreated. HAT is
a Neglected Tropical Disease (NTD) that was an epidemic a few decades ago, but is now becoming
a rare disease (https://www.who.int/trypanosomiasis_african/news/progress-on-eliminating-hat-as-
public-health-problem/en/). We review the activities in the run-up to this achievement, the resources
available and what is needed to sustain this level of control in the campaign for the elimination of HAT.
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2. Human Infectivity
Most of the African trypanosomes, except for T. b. gambiense and T. b. rhodesiense, are
sensitive to apolipoprotein-L1-mediated lysis by the human serum [3]. Evasion of this lysis by
T. b. rhodesiense in human serum is by expressing the serum resistance-associated (SRA) protein,
which binds apolipoprotein-L1 in the endosomal-lysosomal system and prevents pore formation [4].
However, resistance to lysis by T. b. gambiense is a multifactorial process involving the uptake of
reduced trypanolytic factor (TLF1) by an alternative form of T. b. gambiense haptoglobin-haemoglobin
receptor (TbHpHbR), T. b. gambiense-specific glycoprotein (TgsGP) mediated endosomal membrane
stiffening and a rise in the lysosomal cysteine protease activity [5,6].
3. Parasite Life Cycle
T. brucei enters the mammal to start its lifecycle during a bloodmeal by an infected tsetse fly, which
injects the metacyclic trypomastigote forms of the parasite in its saliva into the skin [7]. This injection is
accompanied by the formation of a skin lesion or chancre at the position of the tsetse bite. The chancre
which appears as early as the fifth day post-infection varies in diameter from a few millimeters to
several centimeters [8] and is denoted by a severe host inflammatory reaction usually associated
with T. b. rhodesiense infection and usually resolves within three weeks of infection [9]. The chancre
marks the invasion of the lymphatic organs by the trypanosomes. After deposition in the skin,
metacyclics develop into the long slender bloodstream forms that populate the blood and tissue fluids
of mammals [10]. The long slender bloodstream forms can survive the immune attack of the host
because they express variant surface glycoproteins (VSG) on their cell surface [11–13]. At maximum
parasitemia, the bloodstream form trypanosomes differentiate into the short stumpy form, the form
best suited for survival in the tsetse fly [14]. The adaptation in the short stumpy form includes a change
from the parasite’s metabolic requirement for glucose to a dependence on proline which is abundant
in the tsetse fly midgut [15]. In the midgut of the tsetse fly, the short stumpy forms develop into the
procyclic forms with a change in the surface coat expression from VSG to a less dense EP (marked
by an internal repeat of glutamic acid E and proline P) and GPEET (marked by an internal repeat of
glycine G, proline P, glutamic acid E, and Threonine T) procyclin [16]. Following multiplication in the
midgut or proventriculus, procyclic trypanosomes migrate toward the salivary glands, undergoing
an asymmetric cell division to produce a long epimastigote form and a short epimastigote form [17].
Only the short forms are thought to be destined for attachment and proliferation in the fly salivary
gland, where EP procyclin mRNA continues to be expressed although procyclin protein is not detectable
on most parasites. This repression is due to sequences present in the procyclin coding region [18].
Epimastigotes are thought to be the stage at which sexual exchange occurs between trypanosome lines,
with hybrids being detectable in the salivary gland after parasite lines tagged with distinct fluorescent
reporters were transmitted through tsetse flies [19]. The epimastigotes develop into the metacyclics
and reacquire the VSG coat [20]. After detaching from the salivary gland wall, these metacyclics are
infectious to mammals and can be transmitted during a tsetse blood meal.
4. Transmission of HAT
It was observed that though tsetse fly of all species can transmit HAT, the tsetse fly belts are
wider in Sub-Saharan Africa (SSA) than the HAT distribution [21], resulting in areas with the vector
but no disease. Also, tsetse flies infected with T. b. gambiense have been found to produce midgut
infections that fail to develop into mature salivary gland infections [22,23]. Similarly, only 30% of six
field isolates of T. b. gambiense were able to follow through with the life cycle to the salivary gland
stage [24] in Glossina palpalis gambiensis. Conversely, 27 serum-resistant T. brucei strains including
one strain isolated from the tsetse fly, nine strains from cattle (all 10 strains confirmed to be distinct
from T. b. gambiense) and 17 T. b. rhodesiense all were able to produce the metacyclic salivary gland
trypanosomes in tsetse fly 28-days post-infection [25]. These reports suggest that tsetse fly efficiently
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transmits T. b. rhodesiense but not T. b. gambiense. Congenital infection with HAT results from mother
to child transmission and is specifically the diagnosis of HAT in a newborn of an infected mother in
the first five days of life [26,27]. Cases of vertical transmission of HAT reported are mostly due to
T. b. gambiense infection [26,28,29], likely because of the chronic nature of its infection. An interesting
case of a twin birth from a mother suffering from first stage HAT infection challenges our definition
of a congenital infection. One of the twins was diagnosed with HAT at birth while the second twin
was diagnosed six weeks later [30]. Similarly, a 19-month-old son born to a white Portuguese lady
(living in the United States) who had never been to Africa but had a Brazilian partner who was in
Angola on a military mission, was diagnosed with stage 2 gHAT infection. The lady and her partner
were also diagnosed with the same infection and treated [31]. These reports suggest that the diagnosis
of congenital infection may not always be possible in the first five days of life, and the Portuguese
lady’s infection could only have been by sexual transmission. Vertical transmission seems to be a rare
event, but this rarity may be due to the underestimation of this means of transmission, resulting from
missed opportunities for diagnosis because HAT screenings are usually done in villages, and not in
hospitals or well-equipped laboratories [32]. Also, routine tests for HAT in pregnant women are not
being carried out to diagnose and treat infections in pregnant women to reduce vertical transmission.
5. Epidemiology
The most recent trypanosomiasis epidemic occurred in 1970, with most of the cases occurring
in Angola, Congo, Southern Sudan, and the West Nile area of Uganda, and lasted till 1990 when
eflornithine was registered for use in place of melarsoprol for treatment of stage 2 T. b. gambiense
infection [33]. During the period of the epidemic, sleeping sickness replaced HIV/AIDS as the greatest
cause of death in many communities in Angola, South Sudan, and the Democratic Republic of Congo
(DRC) where prevalence of up to 50% was reported [34]. World Health Organization (WHO) established
public-private cooperations with Aventis Pharma (now Sanofi) and Bayer HealthCare in 2000 and
2001 respectively, and renewed in 2006, 2011, and 2016, which enhanced the creation of a WHO
surveillance team, supported endemic countries in their control activities and provided free drugs for
treatment of patients [34]. As a result, the total number of new HAT infections reported per year in
Africa was reduced from 37,991 in 1998 to 1,446 in 2017, with the actual number of cases estimated at
below 10,000 [34]. These numbers are however very likely lower than the true actual number of cases,
since undiagnosed deaths due to sleeping sickness were not considered [35].
The WHO in 2012 set the goal of reducing the impact of sleeping sickness to the level where it
ceases to be a public health problem by 2020 in its NTD roadmap [36]. One of the indicators to monitor
the achievement of this goal was the reduction of the annual number of new cases of HAT to <2000 by
the year 2020 [37]. This goal has already been achieved, thus paving the way for the 2030 goal of total
elimination of transmission of the gambiense HAT (gHAT) to achieve zero cases [38].
6. Diagnostic Tools
Card-agglutination trypanosomiasis test (CATT) is a serological test used for the preliminary
screening for gHAT. It is a cheap, fast test that can be run on fresh or dried blood, plasma or serum [39].
Diagnosis of gHAT infection is subsequently confirmed by microscopic identification of trypanosomes
in blood, lymph nodes or cerebrospinal fluid. CATT tests for T. b. gambiense variable surface antigen
LiTat 1.3 [40]. A reduction in disease burden, as is the case with the HAT now, causes a depreciation in
the positive predictive value of the available diagnostic tests for HAT such as the card agglutination
test for trypanosomes, CATT [41]. In addition, serologic tests are not useful for following the course
of treatment because they give false-positive results, after cure, with antibodies from the previous
exposure. New tests with enhanced sensitivity for HAT detection, therefore, needs to be developed.
Antigen evaluation for new serologic tests found the invariant surface glycoproteins, ISG64 and ISG65,
to be quite reactive to sera from gambiense patients while the SRA displayed a strong reactivity to
sera from rhodesiense patients. VSG LiTat 1.3 and VSG LiTat 1.5 were found to be the among the most
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reactive antigens against both the gambiense and the rhodesiense sera samples [42]. However, none of
the antigens tested was able to react with all positive sera for either gambiense or rhodesiense, suggesting
that at least two antigens need to be combined to develop a test with the sensitivity for effective
disease control. Molecular detection of trypanosome cell-free DNA [43] by loop-mediated isothermal
amplification (LAMP) technique is highly specific and sensitive, requires minimal equipment since
DNA is amplified at a uniform temperature, and can easily be performed by staff with minimal
molecular biology experience [44]. The Foundation of Innovative New Diagnostics (FIND) developed
a LAMP kit for HAT, in association with Eiken Chemical Company of Japan in 2011. The reaction tubes
arrive containing the dried HAT LAMP reagents and can be stored at room temperature, with the
addition of the test sample (fresh or dried blood), the tubes are heated at a constant temperature and
the result visualized under LED light [44].
7. Vaccine Prospect
Despite considerable research, not a single vaccine has so far been developed against either
the HAT or the AAT. Trypanosomes can stay one step ahead of the host immune response and
avoid complete destruction by antigenic variations, which it achieves through VSG switching [11–13].
Other not-so-variable surface proteins were studied, and some were reported as promising vaccine
candidates. For instance, recombinant p15, an intracellular protein of T. b. brucei was found to
provide 100% protection, while the native p15 protein provided 87.5% protection from T. b. brucei
when used to vaccinate mice [45]. However, adenovirus particles lacking p15 (negative control) also
provided a similar level of protection as p15, suggesting that this protection was not mediated by
immune memory cells. It was suggested that such nonspecific immunity conferred by recombinant
proteins might be as a result of contamination with E. coli proteins [46]. Trypanosomes are efficient
in circumventing destruction by the host’s humoral immunity by eliminating the B-cell memory
and sheltering the conserved epitope in preparation for persistent infection [47]. This preliminary
elimination of B-cell memory during infection might be a factor in the failure to develop an efficacious
vaccine. Hence, immunization with the immunodominant VSG failed to produce a comprehensive
defense [47]. A successful attempt to produce an effective vaccine will require dealing with the
ability of the trypanosomes to suppress the host immune response at the initial stage of the infection
just after introduction into the skin by infected tsetse flies [48]. However, since there has been such
significant progress made towards the elimination of HAT without any vaccine, it is pertinent to
consider if vaccines are indispensable to the total elimination of this disease. Also, the lessons learnt
from combating the HAT could be applied to other diseases, such as malaria, where the effort to
develop vaccines is stalling.
8. Chemotherapy
Control of the HAT leans heavily on chemotherapy in the absence of a vaccine. The clinical
progression of the 2 forms of HAT involves two stages, namely stage 1 (early-stage, haemolymphatic)
and stage 2 (late-stage, meningoencephalitic), and each stage responds to a few of the available
trypanocides. Progression to stage 2 of rHAT occurs within a couple of weeks while gHAT advances
more slowly to the late stage, usually within months or years post-infection [49]. Approved drugs for
the treatment of HAT include pentamidine and suramin for early-stage gHAT while suramin is the only
drug for stage 1 rHAT. Melarsoprol, eflornithine, and nifurtimox-eflornithine combination therapy
(NECT) are the approved treatments for stage 2 gHAT, while late-stage rHAT currently responds to
treatment with only melarsoprol [50].
Pentamidine is taken up into the trypanosome cell through the P2 adenosine transporter [51] or
the high-affinity pentamidine transporter (HAPT1 or trypanosome aquaporin 2) and kills the parasite
by disruption of the mitochondrial genome [52], loss of both the kinetoplast and the mitochondrial
membrane potential [53]. Another report found that pentamidine binds to and inhibits trypanosome
aquaporin 2 [54]. Melarsoprol seems to react with the trypanothione dithiol to form an adduct known as
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Mel T which is a mildly strong competitive inhibitor of the parasite’s antioxidant enzyme, trypanothione
reductase [55]. Melarsoprol was also found to inhibit mitosis [53]. Eflornithine exerts its trypanostatic
effect by inhibiting ornithine decarboxylase in trypanosomes, causing a reduction in polyamine
biosynthesis [56] which leads to a fall in the biosynthesis of the trypanosome specific redox-active
metabolite, trypanothione. Uptake of Suramin in trypanosomes through an endocytic pathway
involves the expression of a bloodstream form-specific invariant surface glycoprotein ISG75 [57], and
a variant surface glycoprotein [58]. The mechanism of action of suramin involves the inhibition of
cytokinesis [53] and is amplified by the uptake of ornithine through two amino acid transporters and
its decarboxylation, by ornithine decarboxylase, which is inhibited by eflornithine, hence antagonizing
the action of suramin [59]. Nifurtimox is a prodrug activated by an NADH-dependent, mitochondrially
localized, type I nitroreductase (NTR) to exert its cytotoxic effect [60], which includes the disruption of
the parasite’s mitochondrial membrane potential [53].
These treatments each require intravenous or intramuscular administration, except for nifurtimox
which can be taken orally as a component of NECT (while the eflornithine component is still delivered
intravenously). These drugs are considered suboptimal due to high production cost, toxicity, poor
oral bioavailability, difficulty in drug administration, long treatment regime and low-efficacy [61].
Melarsoprol, for instance, is so toxic that up to one of every 20 late-stage HAT patients that receive
melarsoprol treatment die of a reactive encephalopathy [61]. The nifurtimox-eflornithine combination
therapy (NECT) was brought in because of its lower toxicity and treatment period compared to
melarsoprol or eflornithine alone, but NECT still required seven days of intravenous administration [62],
making it unsuitable for use in resource-poor settings where HAT is endemic.
There is also the problem of drug resistance which greatly reduces the efficacy of the current
trypanocides. Pentamidine, and melarsoprol, resistance is developed as a result of a mutation or loss
of the trypanosome aquaporin 2 [52,63]. Eflornithine resistance arises due to the loss of TbAAT6 [64],
the gene encoding a low-affinity transporter for uncharged amino acids [65]. Resistance to nifurtimox
is a consequence of the down-regulation or reduced activity of NTR [60].
New chemotherapeutic options recently added to the arsenal of HAT trypanocides include
fexnidazole, an orally active nitroimidazole, and the benzoxaborole, SCYX-7158. These will make up
for the shortcomings of the currently licensed trypanocides. Fexinidazole is potentially efficacious
against both T. b. gambiense and T. b. rhodesiense HAT and active against the two stages of the
disease [61]. However, fexinidazole resistance was easily selected for experimentally, thus making
a case for fexinidazole to be used in combination with an unrelated trypanocide [66]. Approval for
the marketing of fexinidazole in the DRC as a once-daily treatment for 10 days against T.b. gambiense
HAT has been granted, making fexinidazole the first new chemical substance to be registered
by DNDi (https://www.dndi.org/2019/media-centre/press-releases/fexinidazole-sleeping-sickness-
approved-democratic-republic-congo/). As a safe oral trypanocide, fexinidazole would simplify
HAT treatment, and if found to be safe for pregnant and nursing mothers, would help combat infections
due to vertical (maternal) transmission of HAT. Similarly, SCYX-7158 (acoziborole) is a single-dose
oral tablet for both disease stages of HAT [67], which is expected to be suitable for administration at
home (https://www.dndi.org/diseases-projects/portfolio/acoziborole/). A couple of other compounds,
including SCYX1330682, SCYX-1608210, and SCYX-2035811 have been kept on hold and will only be
developed in the future if the need arises [50].
9. Prospects for New Drugs
Due to the ever-increasing incidence of drug resistance and the unsatisfactory nature of current
antitrypanosomal drugs, there is a great need for new compounds to be developed into drugs [68,69].
There have been rising interests in the use of natural products as starting materials since they form
the basis of traditional medications and provide a rich plethora of chemicals that hold potential as
new drug leads [70]. Also, they tend to be structurally diverse (providing a vast array of compounds
most probably with distinct resistance profiles from the existing drugs) and have low cytotoxicity,
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high selectivity, and good efficacy [71]. Natural products are secondary metabolites that have been
isolated from natural sources, notably plants and micro-organisms. Some earlier reviews have identified
natural compounds with antitrypanosomal activity [72,73]. This section focuses therefore on natural
products that have been tested against different Trypanosoma species in the last decade with promising
trypanocidal activities (Table 1). From the table, Abruquinones D, A, and L, isoflavonoids from the
plant Abrus precatorius, have the lowest IC50 values (tested against Trypanosoma brucei rhodesiense,
the causative agent of rHAT) with good selectivity (selectivity index >300). However, it is worthy to
note that differences between different laboratories in IC50 values of standard drugs used as controls
make it rather challenging to make a direct comparison between compounds in order to determine the
most active compound. Though some compounds have antitrypanosomal activity worth exploring
further, their poor selectivity does not make them suitable candidates for further studies (for example,
Perovskone B and Cynaropicrin). For most of these compounds, there is a need for a mode of action
studies to be carried out as this would give insight on how the compounds act as well as biochemical
processes that could be targeted in the parasites. While natural products might hold some promise
for new treatments, the process of isolation and characterization of bioactive entities is laborious,
and sometimes bioactivity is compromised during the isolation process. Also, if the starting materials
used for the isolation is insufficient, minimal quantities of bioactive compounds are obtained with
limited compounds for follow-up studies. Difficulties are often encountered synthesizing natural
products due to the complexity of their structures and in some cases, low solubility. Despite these
challenges, natural products remain very vital starting points in the quest for new treatments.
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Table 1. Natural products found to possess promising trypanocidal activities in the last decade.
S/No Class of Compound Name of Compound Source IC50 (µM) Active against Selectivity Index Proposed Mechanism of Action Ref
1 Piperidine Alkaloids (+)-Spectaline Senna spectabilis leaves 0.410 ± 0.010 Trypanosomabrucei rhodesiense 135
Autophagic cell death resulting from mitochondrial damage due
to interference of the sterol synthetic pathway in Trypanosoma
brucei rhodesiense.
[74]
2 Piperidine Alkaloids Iso-6-spectaline Senna spectabilis leaves 0.710 ± 0.010 Trypanosomabrucei rhodesiense 124
Autophagic cell death resulting from mitochondrial damage due
to interference of the sterol synthetic pathway in Trypanosoma
brucei rhodesiense.
[74]
3 Sesquiterpene Isofuranodiene
Smyrnium olusatium
parts (fruits, flowers,
leaves and roots)
3.000 ± 0.800 Trypanosomabrucei brucei 30
Apoptosis resulting from altered mitochondrial membrane
permeability, inhibition of key enzymes involved in metabolism
such as dihydrofolate reductase, reactivity with functional
groups of biological molecules due to electron delocalization of
the furan moiety.
[75]
4 Diterpene 16α-hydroxycleroda-3,13(14)-Z- dien-15,16-olide
Polyalthia longifolia
leaves
0.380 ± 0.050
µg/mL
Trypanosoma
brucei brucei >526
Disruption of biological membranes in the parasite – leading to
decreased fluidity, inhibition of membrane proteins hence
signaling and transport.
[76]
5 Sesquiterpene lactone Deoxyelephantopin Elephantopus scaberleaves 0.070 ± 0.015
Trypanosoma
brucei rhodesiense 65
Inactivation of the immune system, due to bond formation with
panthione, thereby exposing parasites to oxidative damage. [77]
6 Sesquiterpene lactone Vernodalin Vernonia cinerascensleaves 0.160 ± 0.040
Trypanosoma
brucei rhodesiense 35 - [78]
7 Sesquiterpene lactone Vernolide Vernonia cinerascensleaves 0.500 ± 0.010
Trypanosoma
brucei rhodesiense 13 - [78]
8 Diterpene glycoside Cupacinoside Cupania cinereal <10 Trypanosomabrucei rhodesiense - [79]
9 Pentacyclictriterpenoid Taraxerol Cupania cinereal <10
Trypanosoma
brucei rhodesiense - - [79]
10 Triterpenic acid Ursolic acid Keetia leucantha 2.190 ± 0.438 Trypanosomabrucei brucei -
- Not stated. Similar compounds had previously been identified
in other plants. [80]
11 Triterpenic acid Oleanolic acid Keetia leucantha 6.131 ± 1.095 Trypanosomabrucei brucei -
- Not stated. Similar compounds had previously been identified
in other plants. [80]
12 Sesquiterpene lactone Cynaropicrin
Centaurea salmantica L.
aerial parts/Cynara
scolymus
0.280 ± 0.01 Trypanosomabrucei rhodesiense 8 Affected cell proliferation in bloodstream forms. [81]
13 Monoterpeneglycosides
(3S, 6R) cis-linalool 3,6
oxide, O-β-D-
xylopyranosyl-(1”→6′)-
β-D-glucopyranoside
Vangueria edulis 8.180 µg/mL Trypanosomabrucei brucei - - [82]
14 Monoterpeneglycosides
Quercetin-7-o-α-
L-rhamnopyranoside Vangueria edulis 9.020 µg/mL
Trypanosoma
brucei brucei - - [82]
15 Bromopyrrolealkaloids Dibromopalau’amine Axinella verrucose 0.460 µg/mL
Trypanosoma
brucei rhodesiense ~10
Identified structural motifs in the compound associated with
trypanocidal activity. [83]
16 Bromopyrrolealkaloids Longamide Agelas dispar 4.936
Trypanosoma
brucei rhodesiense -
Identified structural motifs in the compound associated with
trypanocidal activity. [83]
17 Bromopyrrolealkaloids Sceptrin
Four different Agelas
sponges (A. conifera, A.
clathrodes, A. longissima,
A. dispar)
15.654 Trypanosomabrucei rhodesiense -
Identified structural motifs in the compound associated with
trypanocidal activity. [83]
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Table 1. Cont.
S/No Class of Compound Name of Compound Source IC50 (µM) Active against Selectivity Index Proposed Mechanism of Action Ref
18 Bromopyrrolealkaloids Spongiacidin B Axinella verrucose 13.580 µg/mL
Trypanosoma
brucei rhodesiense -
Identified structural motifs in the compound associated with
trypanocidal activity. [83]
19 Sesquiterpene lactone Xanthatin Xanthium strumariumleaves 10.881
Trypanosoma
brucei brucei 20
Weak irreversible inhibition of trypanothione reductase,
inhibition of Prostaglandin E synthesis and 5-lipoxygenase
activity thereby inducing apoptosis. Reduction in mitochondrial
membrane potential.
[84]
20 Triterpenoid saponins
Heinsiagenin A 3-O-[α-
L-rhamnopyranosyl-(1→2)-
β-Dglucopyranosyl-
(1→2)]-β-D-glucopyranoside
Mussaenda luteola aerial
parts 8.800±0.640
Trypanosoma
brucei brucei >10 - [82]
21 Triterpenoid saponins
Heinsiagenin A 3-O-[α-
L-rhamnopyranosyl(1→2)-
β-D-glucopyranosyl-(1→2)]-
[β-D-glucopyranosyl-
(1→4)]-β-D-
glucopyranoside
Mussaenda luteola aerial
parts 2.570 ± 0.640
Trypanosoma
brucei brucei >10 - [82]
22 Triterpenoid saponins
2α-hydroxyheinsiagenin A
3-O-[α-L-rhamnopyranosyl-
(1→2)-β-D-glucopyranosyl-
(1→2)]-β-Dglucopyranoside
Mussaenda luteola aerial
parts 2.610 ± 0.090
Trypanosoma
brucei brucei >10 - [82]
23 Triterpenoid saponins
2α-hydroxyheinsiagenin A
3- O-[β-D-glucopyranosyl-
(1→2)]-[β-Dglucopyranosyl-
(1→4)]-β-D-glucopyranoside
Mussaenda luteola aerial
parts 2.840 ± 0.390
Trypanosoma
brucei brucei >10 - [82]
24 Triterpenoid Salvadione C Salvia hydrangea aerialparts 4.330 ± 0.240
Trypanosoma
brucei rhodesiense 43 - [85]
25 Triterpenoid Perovskone B Salvia hydrangea aerialparts 15.920 ± 0.720
Trypanosoma
brucei rhodesiense 1 - [85]
26 Isoflavonoids Abruquinones K Abrus precatorius 0.110 ± 0.053 Trypanosomabrucei rhodesiense 509 - [86]
27 Isoflavonoids Abruquinones L Abrus precatorius 0.020 ± 0.003 Trypanosomabrucei rhodesiense 374 - [86]
28 Isoflavonoids Abruquinones A Abrus precatorius 0.020 ± 0.003 Trypanosomabrucei rhodesiense 1379 - [86]
29 Isoflavonoids Abruquinones D Abrus precatorius 0.010 ± 0.001 Trypanosomabrucei rhodesiense 668 - [86]
30 Lanosanetriterpenoids Hexatenuins A Hexagonia tenuis (Fungi) 0.570 µg/mL
Trypanosoma
brucei brucei - - [87]
31 Lanosanetriterpenoids Hexatenuins B Hexagonia tenuis (Fungi) 8.600 µg/mL
Trypanosoma
brucei brucei - - [87]
32 Lanosanetriterpenoids Hexatenuins C Hexagonia tenuis (Fungi) 5.620 µg/mL
Trypanosoma
brucei brucei - - [87]
Pathogens 2019, 8, 135 9 of 18
10. Vector Control
Tsetse flies belong to the genus Glossina which includes three subgenera (namely, subgenus
Nemorhina, also known as the Palpalis group, subgenus Glossina sensu stricto, or the Morsitans group,
and subgenus Austenina also called the Fusca group) that together contain 31 species and sub-species,
all of which can potentially transmit trypanosomes, but the most important epidemiologically are
the Morsitans and Palpalis groups, found mostly in natural savannahs and riverine forest vegetation
respectively [88–90]. gHAT is almost totally transmitted by either Glossina fuscipes or Glossina palpalis
subspecies while rHAT can be transmitted by any of G. fuscipes SL, G. swynnertoni, G. morsitans morsitans
and G. pallidipes, but AAT transmission seems to be geographically dependent, with the Mortisans
transmitting in East and South Africa while Palpalis group dominate West Africa [90].
Tsetse control can be carried out to achieve an integrated control or total eradication of the
vector [91]. Integrated control of tsetse fly is carried out by livestock farmers using either the
insecticide-treated cattle technique [92,93] or insecticide-treated (odor-baited) targets [94]. Strategies
for vector eradication include the sequential aerosol technique [95] involving the aerial spraying of
pyrethroid formulations and the sterile insect technique [96] which unleashes irradiated males to
sterilize wild females when they mate with them. A method described as paratransgenesis reduces
or eliminates the ability of tsetse flies to transmit trypanosomes by compromising their microbiome
through genetic modification. Genetically modified Sodalis introduced into the larval stages was found
to be capable of efficiently colonizing the succeeding generations of offsprings, hence demonstrating
that Sodalis can be employed as a vehicle to deliver foreign transgenes for the transformation of Glossina
morsitans morsitans in paratransgenesis [97]. Other methods of control include ground spraying and
bush clearing and game destruction. Odor-baited targets are more economical than aerial spraying
and less harmful to the environment than insecticidal ground spraying, game destruction, or habitat
clearance. However, it has only been used for extensive tsetse elimination in Zimbabwe and in the
Zambian West Province because of the cost, the logistic requirements, and the need for government
commitment [94]. Repellents can also be employed for vector control, for instance, the push-pull control
method employs repellents to push the tsetse flies towards stationary visual attractants designed to kill
the flies [98]. The repellent mix called waterbuck repellent compounds (WRC) and 4-methylguaiacol
which were known Mortisan group tsetse fly repellents were tested for their effects on the Palpalis
group and found to effectively repel Glossina fuscipes fuscipes [98]. Similarly, unrefined zebra skin odour,
as well as a chemical mix with identical odor, was found to significantly repel Glossina pallidipes [99].
The African Union in 2000 adopted a policy to eradicate tsetse flies and trypanosomiasis from
Africa following the successful and enduring elimination of G. austeni from Unguja Island in Zanzibar
using the sterile insect technique, and the subsequent disappearance of the AAT disease [96]. This led
to the setting up of the Pan African Tsetse and Trypanosomiasis Eradication Campaign (PATTEC)
to coordinate programs aimed at tsetse fly and trypanosomiasis elimination across the continent of
Africa [96]. However, the sterile insecticide technique was recommended for use after the tsetse
population has initially been reduced by other methods, such as the combination of odor-baited targets
and insecticide-treated cattle [94].
11. Challenges Facing HAT Elimination
As stated earlier, the notional global target of achieving a less than 2000 reported HAT cases by
2020 set by the WHO has already been met. The initial figures gathered by WHO showed reported
cases in 2017 to be less than 1500 [34]. Despite this remarkable achievement, HAT remains a public
health problem in some countries. This setback is due to a combination of factors converging to limit
the progress towards elimination of HAT.
One of the most critical factors impeding the achievement of the WHO’s ambitious goal of
elimination of HAT is identifying the level of drug resistance in the trypanosome populations in
Africa. Even the anticipated introduction of the new treatment, fexinidazole, does not solve this
problem as it has been found to be cross-resistant with the existing essential drug, nifurtimox [100].
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Thus, an increased understanding of the incidence of resistant alleles (including for nifurtimox) in
clinical isolates is vital to winning the end-game in finally erasing this scourge from sub-Saharan Africa.
However, to date, very little is known about the spread of such resistance genes in the trypanosome
species responsible for HAT in Africa.
Another of such factors is accessibility, which is still limited in some endemic areas [41], cases even
go undetected or reported in some remote areas lacking access to medical facilities. This means that
the actual figure may be higher than the <1500 cases reported by the WHO, and this is a real challenge.
There is a growing body of evidence indicating that asymptomatic carriers persist in certain foci
after medical surveys and cannot be diagnosed passively [101–103]. Similarly, both the skin [104,105]
and adipose tissue [106] have been found recently to be the sites of multiplication of trypanosomes.
This could explain the existence of serologically positive patients showing no trypanosomes in the
blood. These seemingly aparasitaemic hosts harbored trypanosomes that were able to infect the tsetse
flies [107]. Recent findings suggest that the infection could be from skin-dwelling trypanosomes
taken up with the blood meal [105]. The problem here is that treatment is presently only provided
for microscopy-positive subjects, leaving a percentage of the infected population of undetermined
significance untreated.
The presence and emergence of higher-burden competing diseases is also an identified factor
affecting the HAT elimination program. From a historical point of view, a successful elimination
campaign can limit itself when national health authorities are struggling to defend the continued
investment in the face of declining case numbers while at the same time confronting and/or prioritizing
other, higher-burden diseases. A classic example of this is Guinea, where the Ebola outbreak of 2014
led to an interruption of the national HAT control program, and a corresponding increase in the HAT
burden [108]. Political and social instability, inappropriate funding, and lack of ownership of the HAT
problem by endemic countries are also part of the challenges facing the program to eliminate HAT.
The animal reservoirs of T. b. gambiense reported in West [109–112] and Central [113,114] Africa
are additional factors that must be considered for a successful elimination program. It has been
observed that patient-derived T. b. gambiense strains are capable of cycling between tsetse flies and
various animal species without losing infectivity to humans [115]. Now, more attention is being
given to cattle as a reservoir of trypanosomes, as several reports have underlined the significance of
domestic and wild animals as important factors in the spreading of T. b. rhodesiense [114,116]. Studies
have shown that domestic pigs could play an important role in the epidemiology of trypanosomiasis
both in humans and animals [117]. Pigs are becoming important as a source of food and income
earner for smallholder livestock farmers, especially in areas where AAT and both forms of HAT are
endemic. Therefore, efforts directed towards bovine trypanosomiasis alone while ignoring other
potential domestic animal reservoirs might be a contributory factor to the persistence of sleeping
sickness in Africa. For instance, in a recent study of trypanosome species circulating in livestock in
two HAT foci of Côte d’Ivoire, pigs and cattle were identified as reservoirs of T. b. gambiense [117].
A potential contradiction would arise when a very low number of new infections of HAT presents
a reason for demotivation [103]. The potential complacency would be a cog in the wheel of progress
towards this elimination drive. Donors’ demotivation when faced with the huge amount of money
needed to be spent on surveillance and drug provision when few or no new patient(s) are being
detected, technicians’ demotivation when thousands of people are being tested without finding new
infections, the inhabitants being demotivated to participate in unending medical surveys with no new
infection being found, are just a few. The event that hindered HAT elimination in the 1960s must be
totally avoided to ensure the ultimate achievement of the set goal. Therefore, to achieve the WHO
elimination goal, HAT control needs to be approached using the One Health strategy. This approach
involves the formulation and execution of programs, policies, legislations, and research jointly by
the agencies in charge of HAT and AAT elimination. Communication between these two groups of
agencies is necessary to improve the public health outcome since trypanosomiasis can be zoonotic
Pathogens 2019, 8, 135 11 of 18
(https://www.who.int/features/qa/one-health/en/). Possible synergy at the interface of One Health can
facilitate the simultaneous elimination of both AAT and HAT.
12. Insights for the Future
Elimination of a disease can be achieved by ensuring that Rc (reproduction number of the disease
in the presence of control) is below 1 for a significant amount of time [118]. For HAT, this will require
the combined application of vector control methods, sensitive diagnostic tests, and trypanocidal drugs.
T. b. rhodesiense is zoonotic, with wild and domestic animals as carriers. Since its infection in humans is
usually acute, causing the infected subjects to try to obtain treatment soon after infection, the most
practical method of combating rHAT would be the provision of excellent diagnostic tools and increasing
the treatment options available at health centers in endemic areas. This approach would enhance early
diagnosis and treatment of infection, and in combination with vector control, would ultimately break
the transmission of this disease [110]. Conversely, humans are the reservoirs for T. b. gambiense [119],
with HAT progressing for years if not treated [120]. Animal hosts of T. b. gambiense have also been
identified [121,122], and this could be an important factor when considering the transmission of this
disease. The three-way method suggested for gHAT control includes active case detection using mobile
teams, passive case detection, treatment at hospitals and health centers, and vector control [110].
Results of recent simulations suggest that detection and treatment of gHAT infections using the
currently registered trypanocides and diagnostic methods is ineffective and less likely to result in
full elimination of gHAT by 2030 [67]. The introduction of fexinidazole and acoziborole is expected
to remove side effects due to toxicity, reduce the cost of treatment and remove the requirement
of hospitalization for treatment. If these new treatment regimens are supported with sensitive,
point-of-care rapid diagnostic equipment, then case detection and treatment can easily be carried out
in all locations: markets, schools, churches, offices, and so on, in endemic communities. With portable
diagnostic equipment, the employment of motorbike surveillance teams for remote communities
becomes feasible. Insecticide-treated targets can also be replaced with tiny targets that are very much
smaller and cheaper than the odor-baited targets [67].
13. Conclusions
With the early achievement of the 2020 goal of a drastic reduction in the number of cases of HAT
(thus reducing concerns of HAT as a public health problem), the goal of its sustainable elimination
seems very promising. However, when one considers the resources presently available for this purpose,
the goal of eliminating HAT seems very far-fetched. Diagnostic tools available needs to be improved
to ensure prompt detection and treatment. New drugs for single and combination therapies which are
non-toxic, affordable, easily administered, and with no cross-resistance to existing drugs need to be
introduced. Drug resistance in African populations need to be monitored and characterized, and then
active case-finding and surveillance need to be sustained until elimination is achieved. These would
require a concerted investment of resources.
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